Publications by authors named "Jeffrey Probstfield"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

9,954

Total Likes

265

Extended Reach

262,420

Social Features

27
B
Basal insulin and cardiovascular and other outcomes in dysglycemia.

July 2012

Videos about Article: user user user

3 6 24 8 15

View All Article and Social Media Activity
E
Effect of Famotidine on Outcomes in Pulmonary Arterial Hypertension: A Randomized Controlled Trial.
Peter J Leary, Samuel G Rayner, Kelley R H Branch, Laurie Hogl, Nancy M Liston, Jeffrey L Probstfield

Chest· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective.
Andre Lamy, John Eikelboom, Wesley Tong, Fei Yuan, Shrikant I Bangdiwala, Jeffrey Probstfield

Am J Cardiovasc Drugs· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostic yield, safety, and outcomes of Head-to-pelvis sudden death CT imaging in post arrest care: The CT FIRST cohort study.
Kelley R H Branch, Medley O Gatewood, Peter J Kudenchuk, Charles Maynard, Michael R Sayre, Jeffrey L Probstfield

Resuscitation· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global Variations in Heart Failure Etiology, Management, and Outcomes.

JAMA· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: The ELIXA trial.
Hertzel C Gerstein, Emil Wolsk, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Jeffrey L Probstfield

Diabetes Obes Metab· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Total events and net clinical benefit of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: The COMPASS trial.
Kelley R H Branch, Jeffrey L Probstfield, Jackie Bosch, Deepak L Bhatt, Aldo P Maggioni

Am Heart J· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Scoping review of echocardiographic parameters associated with diagnosis and prognosis after resuscitated sudden cardiac arrest.
Linda Liu, Aris Karatasakis, Peter J Kudenchuk, James N Kirkpatrick, Michael R Sayre, Jeffrey L Probstfield

Resuscitation· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial.
John W Eikelboom, Jacqueline Bosch, Stuart J Connolly, Jessica Tyrwitt, Keith A A Fox, Jeffrey L Probstfield

Eur Heart J Cardiovasc Pharmacother· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to the letter regarding the article 'Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial'.
Kelley R H Branch, Hertzel C Gerstein, Jeffrey L Probstfield

Eur J Heart Fail· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial.
Kelley R H Branch, Gilles R Dagenais, Alvaro Avezum, Jan Basile, Ignacio Conget, Jeffrey L Probstfield

Eur J Heart Fail· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protein Biomarkers and Cardiovascular Outcomes in People With Type 2 Diabetes and Acute Coronary Syndrome: The ELIXA Biomarker Study.
Hertzel C Gerstein, Sibylle Hess, Brian Claggett, Kenneth Dickstein, Lars Kober, Jeffrey L Probstfield

Diabetes Care· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel kidney disease index reflecting both the albumin-to-creatinine ratio and estimated glomerular filtration rate, predicted cardiovascular and kidney outcomes in type 2 diabetes.
Hertzel C Gerstein, Chinthanie Ramasundarahettige, Alvero Avezum, Jan Basile, Ignacio Conget, Jeffrey Probstfield

Cardiovasc Diabetol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial.
Tali Cukierman-Yaffe, Hertzel C Gerstein, Jan Basile, M Angelyn Bethel, Ernesto G Cardona-Muñoz, Jeffrey Probstfield

J Clin Endocrinol Metab· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trial.
Peter J Raubenheimer, William C Cushman, Alvaro Avezum, Jan Basile, Ignacio Conget, Jeffrey Probstfield

Diabetes Obes Metab· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk Estimates of Imminent Cardiovascular Death and Heart Failure Hospitalization Are Improved Using Serial Natriuretic Peptide Measurements in Patients With Coronary Artery Disease and Type 2 Diabetes.
Emil Wolsk, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Jeffrey L Probstfield

J Am Heart Assoc· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Niacin Increases Atherogenic Proteins in High-Density Lipoprotein of Statin-Treated Subjects.
Graziella E Ronsein, Tomas Vaisar, W Sean Davidson, Karin E Bornfeldt, Jeffrey L Probstfield

Arterioscler Thromb Vasc Biol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial.
Harpreet S Bajaj, Hertzel C Gerstein, Purnima Rao-Melacini, Jan Basile, Helen Colhoun, Jeffrey Probstfield

Lancet Diabetes Endocrinol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin.
Giulia Ferrannini, Hertzel Gerstein, Helen Martina Colhoun, Gilles R Dagenais, Rafael Diaz, Jeffrey Probstfield

Eur Heart J· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease.
Gilles R Dagenais, Leanne Dyal, Jacqueline J Bosch, Darryl P Leong, Victor Aboyans, Jeffrey L Probstfield

Heart· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early head-to-pelvis computed tomography in out-of-hospital circulatory arrest without obvious etiology.
Kelley R H Branch, Jared Strote, Martin Gunn, Charles Maynard, Peter J Kudenchuk, Jeffrey L Probstfield

Acad Emerg Med· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis.
Gilles R Dagenais, Lars Rydén, Lawrence A Leiter, Mark Lakshmanan, Leanne Dyal, Jeffrey L Probstfield

Cardiovasc Diabetol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy.
Mukul Sharma, Robert G Hart, Eric E Smith, Jacqueline Bosch, John W Eikelboom, Jeffrey L Probstfield

Stroke· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial.
Magnus O Wijkman, Brian Claggett, Rafael Diaz, Hertzel C Gerstein, Lars Køber, Jeffrey Probstfield

Cardiovasc Diabetol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostic accuracy of early computed tomographic coronary angiography to detect coronary artery disease after out-of-hospital circulatory arrest.
Kelley R Branch, Ravi Hira, Robin Brusen, Charles Maynard, Peter J Kudenchuk, Jeffrey L Probstfield

Resuscitation· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial.
Tali Cukierman-Yaffe, Hertzel C Gerstein, Helen M Colhoun, Rafael Diaz, Luis-Emilio García-Pérez, Jeffrey Probstfield

Lancet Neurol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis